Key result
Anticoagulation reversal strategies for dabigatran and rivaroxaban lack reliable guidance and specific agents compared to warfarin, rendering current treatment strategies largely empirical.
Why the study?
What are the current recommendations and effective strategies for reversing oral anticoagulants (warfarin, dabigatran, rivaroxaban) in bleeding or preprocedural patients?
Population
Patients treated with oral anticoagulants who are at a heightened risk of bleeding, actively bleeding, or in…
Design
Systematic_review
Authors
Loading...
Empirical reversal for dabigatran and rivaroxaban warrants clinical caution; confirms gaps versus warfarin and extends need for specific agents.
Systematic Review
What are the current recommendations and effective strategies for reversing oral anticoagulants (warfarin, dabigatran, rivaroxaban) in bleeding or preprocedural patients?
This review highlights the established guidelines for warfarin reversal and the critical knowledge gaps and empirical nature of current reversal strategies for dabigatran and rivaroxaban.
Thigpen et al. (2013) conducted a systematic review in Patients on oral anticoagulants at heightened risk of bleeding, actively bleeding, or needing preprocedural reversal. Anticoagulation reversal strategies (warfarin, dabigatran, rivaroxaban) was evaluated. Anticoagulation reversal strategies for dabigatran and rivaroxaban lack reliable guidance and specific agents compared to warfarin, rendering current treatment strategies largely empirical.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: